FY2017 EPS Estimates for CVS Health Corporation Boosted by Analyst (CVS)

CVS Health Corporation (NYSE:CVS) – Equities research analysts at Jefferies Group raised their FY2017 EPS estimates for shares of CVS Health Corporation in a note issued to investors on Friday. Jefferies Group analyst B. Tanquilut now forecasts that the pharmacy operator will post earnings of $5.88 per share for the year, up from their previous estimate of $5.82. Jefferies Group currently has a “Hold” rating and a $86.00 target price on the stock. Jefferies Group also issued estimates for CVS Health Corporation’s Q4 2017 earnings at $1.90 EPS and FY2018 earnings at $6.34 EPS.

CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings data on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.02. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The company had revenue of $45.69 billion during the quarter, compared to the consensus estimate of $45.36 billion. During the same period in the previous year, the company posted $1.32 EPS. The firm’s revenue was up 4.5% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/20/fy2017-eps-estimates-for-cvs-health-corporation-boosted-by-analyst-cvs.html.

CVS has been the subject of a number of other reports. Needham & Company LLC restated a “hold” rating on shares of CVS Health Corporation in a research report on Sunday, September 10th. ValuEngine lowered CVS Health Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub lowered CVS Health Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 25th. Guggenheim reaffirmed a “buy” rating on shares of CVS Health Corporation in a research note on Monday, July 3rd. Finally, Vetr raised CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $87.97 price target on the stock in a research note on Wednesday, May 24th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $90.58.

CVS Health Corporation (NYSE CVS) opened at 83.10 on Monday. The company has a market capitalization of $84.48 billion, a P/E ratio of 16.55 and a beta of 0.92. CVS Health Corporation has a 1-year low of $69.30 and a 1-year high of $90.85. The firm has a 50-day moving average price of $79.11 and a 200 day moving average price of $78.98.

The company also recently announced a quarterly dividend, which will be paid on Friday, November 3rd. Investors of record on Tuesday, October 24th will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.41%. CVS Health Corporation’s dividend payout ratio (DPR) is presently 39.92%.

In other CVS Health Corporation news, EVP Helena Foulkes sold 20,333 shares of the stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $80.00, for a total transaction of $1,626,640.00. Following the completion of the sale, the executive vice president now directly owns 59,301 shares of the company’s stock, valued at approximately $4,744,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas M. Moriarty sold 90,267 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.61, for a total value of $7,186,155.87. Following the sale, the executive vice president now directly owns 70,102 shares of the company’s stock, valued at $5,580,820.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 716,411 shares of company stock valued at $58,277,271. Insiders own 0.61% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CVS. Fieldpoint Private Securities LLC lifted its position in CVS Health Corporation by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 1,000 shares during the period. Mercer Capital Advisers Inc. acquired a new stake in CVS Health Corporation during the 1st quarter worth approximately $118,000. MPS Loria Financial Planners LLC acquired a new stake in CVS Health Corporation during the 2nd quarter worth approximately $119,000. Gemmer Asset Management LLC lifted its position in CVS Health Corporation by 15.3% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after acquiring an additional 200 shares during the period. Finally, TB Alternative Assets Ltd. acquired a new stake in CVS Health Corporation during the 2nd quarter worth approximately $121,000. 81.49% of the stock is owned by institutional investors.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Earnings History and Estimates for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply